Spero Therapeutics, Inc.
SPRO Healthcare Biotechnology
Spero Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $66.8 million, up 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 95.6%, EPS fell 433.3% and free cash flow grew 69.7%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow SPRO
Spero Therapeutics, Inc. (SPRO) P/E ratio
As of 16 October 2026, Spero Therapeutics, Inc. (SPRO) trades at a P/E ratio of 7.9×. Over the past ten years it has ranged from 0.0× (December 2025) to 147× (December 2023); the current reading is higher than 86% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 15.5× | — |
| FY2024 | 0.0× | — |
| FY2023 | 3.5× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 8.7× | (44.21%) |
| Dec 2025 | 15.5× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CSBR Champions Oncology, Inc. compare | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| XBIT XBiotech Inc. compare | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. | 7.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)